BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPS

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) issued its earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.18, Zacks reports.

BridgeBio Oncology Therapeutics Stock Up 2.2%

BBOT stock traded up $0.22 during midday trading on Friday, hitting $10.11. 177,883 shares of the company’s stock were exchanged, compared to its average volume of 324,556. BridgeBio Oncology Therapeutics has a 12-month low of $8.50 and a 12-month high of $14.87. The company has a market capitalization of $808.69 million, a PE ratio of -9.82 and a beta of 0.28.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on BBOT shares. Stifel Nicolaus initiated coverage on shares of BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They set a “buy” rating and a $23.00 price target on the stock. Weiss Ratings began coverage on BridgeBio Oncology Therapeutics in a research note on Wednesday, January 14th. They issued a “sell (d+)” rating for the company. HC Wainwright boosted their price target on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Raymond James Financial upgraded BridgeBio Oncology Therapeutics to a “moderate buy” rating in a report on Friday, January 9th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, BridgeBio Oncology Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.00.

Institutional Trading of BridgeBio Oncology Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in BBOT. XTX Topco Ltd boosted its stake in BridgeBio Oncology Therapeutics by 22.4% during the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock valued at $358,000 after acquiring an additional 5,249 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $162,000. Paradigm Biocapital Advisors LP lifted its position in shares of BridgeBio Oncology Therapeutics by 21.2% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock worth $28,317,000 after purchasing an additional 395,608 shares during the last quarter. Laurion Capital Management LP lifted its position in shares of BridgeBio Oncology Therapeutics by 40.1% during the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock worth $18,341,000 after purchasing an additional 419,138 shares during the last quarter. Finally, Persistent Asset Partners Ltd acquired a new position in BridgeBio Oncology Therapeutics in the fourth quarter worth about $107,000. Institutional investors own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.